Homoharringtonine suppresses gastric cancer progression by targeting PI3K/ AKT/FOXO pathway and impairing the GSH–GPX4 antioxidant axis
Cancer Chemotherapy and Pharmacology · 29.04.2026 · 96 (1)
DOI: 10.1007/s00280-026-04893-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 29.04.2026. Verfasst von Xiaonan Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shaoxing Central Hospital, The Central Affiliated Hospital, Shaoxing University, Huayu Road 1, Keqiao District, Shaoxing, 312…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Homoharringtonine, Phospholipid Hydroperoxide Glutathione Peroxidase. Die Arbeit nennt 44 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To investigate the unexplored therapeutic potential and identify the specific molecular targets of homoharringtonine (HHT) in gastric cancer (GC). METHODS: HHT’s efficacy was evaluated in GC cell lines (MKN1/MKN45), normal epithelial cells (GES-1), and an HGC27 xenograft model. Mechanisms were investigated using RNA-sequencing, microscale thermophoresis (MST), molecular docking, and biochemical assays. RESULTS: HHT suppressed GC cell proliferation and migration, inducing G1-phase arrest and apoptosis, while demonstrating lower cytotoxicity toward normal GES-1 cells. MST and docking assays confirmed that HHT directly and stably binds to AKT (KD= 6.496 nM) and suppresses the PI3K/AKT/FOXO/GSK3β signaling pathway. Concurrently, transcriptomic profiling and experimental validation showed that HHT disrupts glutathione metabolism. It depleted intracellular GSH and downregulated GPX4, triggering ferroptosis-like oxidative damage and mitochondrial cristae loss. In vivo, HHT inhibited GC xenograft tumor growth without causing systemic toxicity, which was accompanied by decreased Ki-67 and increased Caspase-3 expression. CONCLUSION: HHT inhibits GC progression by suppressing AKT-mediated tumor growth and inducing GPX4-dependent ferroptosis. These findings highlight HHT as a promising targeted therapeutic for GC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Shaoxing Central Hospital, The Central Affiliated Hospital, Shaoxing University, Huayu Road 1, Keqiao District, Shaoxing, 312030, Zhejiang, China.
- Department of Gastroenterology, The First People's Hospital Yongkang, Jinhua, 321000, China.
- Department of General Surgery, The Chengdu Fifth People's Hospital, Chengdu, 611130, China.
- Department of Pharmacy, Shaoxing Central Hospital, The Central Affiliated Hospital, Shaoxing University, Huayu Road 1, Keqiao District, Shaoxing, 312030, Zhejiang, China. zyzlcl@126.com.
- Department of Pharmacy, Shaoxing Central Hospital, The Central Affiliated Hospital, Shaoxing University, Huayu Road 1, Keqiao District, Shaoxing, 312030, Zhejiang, China. guojingjing-www@163.com.
Zitieren
APA
Wang, X., Ying, X., Lv, S., Ru, S., Jin, H., Zhang, Y., & Guo, J. (2026). Homoharringtonine suppresses gastric cancer progression by targeting PI3K/ AKT/FOXO pathway and impairing the GSH–GPX4 antioxidant axis. Cancer Chemotherapy and Pharmacology, 96(1). https://doi.org/10.1007/s00280-026-04893-x
Vancouver
Wang X, Ying X, Lv S, Ru S, Jin H, Zhang Y, et al. Homoharringtonine suppresses gastric cancer progression by targeting PI3K/ AKT/FOXO pathway and impairing the GSH–GPX4 antioxidant axis. Cancer Chemotherapy and Pharmacology. 2026;96(1). doi:10.1007/s00280-026-04893-x
BibTeX
@article{Wang2026,
author = {Wang, Xiaonan and Ying, Xiao and Lv, Sunyuan and Ru, Shanshan and Jin, Haonan and Zhang, Yingzhe and Guo, Jingjing},
title = {Homoharringtonine suppresses gastric cancer progression by targeting PI3K/ AKT/FOXO pathway and impairing the GSH–GPX4 antioxidant axis},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2026},
volume = {96},
number = {1},
doi = {10.1007/s00280-026-04893-x}
}
EUVIMED